Acrobat genomics, nanostring, and illumina accelerator collaborate with stanford medicine to discover new drug targets for gene editing-based therapeutics

Foster city, calif.--(business wire)--acrobat genomics, nanostring technologies, inc. (nasdaq:nstg), and the illumina accelerator announced today their collaboration with stanford medicine to discover new drug targets for gene editing-based therapeutics using geomx® digital spatial profiling (dsp) technology. this collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. nanostring's geomx dsp is a powerful spa.
NSTG Ratings Summary
NSTG Quant Ranking